Sensorion announced the appointment of Louis ?Lou? J. Arcudi III as Chief Financial Officer, effective October 7, 2026. Lou Arcudi will be based in the Boston area and will report to Fred Chereau, Chief Executive Officer.
He succeeds Laurene Danon, who has decided to step down as Chief Financial Officer to pursue new opportunities and will continue to advise the Chief Executive Officer to ensure an orderly transition. Lou Arcudi brings extensive financial and operational leadership experience in the biopharmaceutical industry, including Chief Financial Officer and Chief Executive Officer roles at U.S.-listed and private biotechnology companies. Most recently, he served as Chief Financial Officer of Amolyt Pharma, a French clinical-stage company focused on rare endocrine diseases, which raised a $138 million Series C financing in 2023 and was acquired by AstraZeneca in 2024 for up to $1.05 billion.
Prior to Amolyt, he served as Chief Executive Officer of Millendo Therapeutics, where he led the company through its merger with Tempest Therapeutics in 2021, after serving as its Chief Financial Officer from 2018 to 2021. Previously, Lou Arcudi served as Senior Vice President of Operations and Chief Financial Officer of Idera Pharmaceuticals and as Vice President of Finance and Administration of Peptimmune. He also held senior roles at Genzyme Corporation, including Senior Director of Finance and Administration of Genzyme Molecular Oncology and Director of International Finance and Commercial Operations.
Earlier in his career, he held finance positions of increasing responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation. Lou Arcudi holds an MBA from Bryant University and a B.S. in Accounting and Information Systems from the University of Southern New Hampshire. Laurene Danon joined Sensorion as interim Chief Financial Officer in October 2023 and was appointed Chief Financial Officer in June 2024.
During her tenure, she played a key role in financings totaling approximately ?125 million, including the ?60 million financing completed in January 2026, which welcomed Sanofi as a strategic investor alongside leading healthcare specialist investors. She also strengthened the Company's finance function and broadened Sensorion's international investor base, positioning Sensorion to execute on its clinical strategy.
